For clinicians delivering cancer care

Salient Oncology
Updates

Continuous surveillance. Thoughtfully curated—so you don't have to.

Developed by a practicing Oncologist

4:01
▋▋📶
CS
CarcinoS
Week of Mar 30
Up to date · Last scan: 2h ago
PRACTICE IMPACTING ■■■
Tarlatamab improves OS in relapsed SCLC
NEJM · Phase III · FDA Approved
OS HR 0.60 · 13.6 vs 8.3 mo
Nivolumab + AVD approved in untreated cHL
FDA · SWOG S1826 · Hematology
3-yr PFS 91% vs 82%
Aca + venetoclax all-oral approved in CLL
FDA · AMPLIFY · First fixed-duration
Practice-changing
INCREMENTAL ■■ 2 updates ›
TALAPRO-2 final OS in mCRPC
The Lancet · Phase III · GU
OS HR 0.80 · 45.8 vs 37.0 mo
Relacorilant approved in platinum-resistant ovarian Ca
FDA · ROSELLA · Gynecologic
OS HR 0.65 · 16.0 vs 11.9 mo
HORIZON 4 signals ›
PATINA: palbociclib in HR+/HER2+ BC
NEJM · Phase III · Breast
Belzutifan + lenvatinib vs cabozantinib
ASCO GU 2026 · Phase III · RCC
Home
🔔Updates
•••More
Practice-Impacting Updates
Studies with immediate clinical impact for oncologists
Incremental Updates
Important studies, not practice changing
Horizon Discoveries
Emerging or early new concepts that may be impactful in the future

CarcinoS quietly monitors the oncology literature and alerts only when practice impacting evidence emerges

“Staying current in oncology is a challenge. CarcinoS allows me to focus on patient care while feeling confident I'm not missing the few updates that actually impact my patients”

Radiation Oncologist  ·  Academic Medical Center

CS
CarcinoS

The oncology literature evolves daily

CarcinoS surfaces and curates what matters

3,000+
Oncology papers
published monthly
worldwide
Hundreds
In major journals
Limited
Time to find and
read them all
Atezolizumab + carboplatin in ES-SCLC · NEJM · Phase III
FOLFOX vs FOLFIRI first-line mCRC · JCO · Phase III
Tarlatamab OS benefit in relapsed SCLC · NEJM■■■
Sacituzumab govitecan in HR+ mBC · ASCO 2026
Lenvatinib + everolimus RCC subgroup · Lancet Oncol
Olaparib maintenance BRCA2+ pancreatic · NEJM
Nivolumab + AVD in untreated cHL · FDA■■■
Cabozantinib + atezolizumab HCC phase II · JCO
Pembrolizumab neoadjuvant TNBC 3-yr OS · ASCO
Tepotinib MET exon 14 NSCLC real-world · Lung Cancer
Iniparib in TNBC: final survival data · Cancer
Aca + venetoclax all-oral CLL · FDA AMPLIFY■■■
Selinexor + bortezomib in MM · Blood · Phase III
Ipilimumab + nivolumab MPM 5-yr OS · Lancet
Lorlatinib vs crizotinib ALK+ NSCLC update · NEJM
Durvalumab stage III NSCLC PACIFIC 5-yr · JTO
Trastuzumab deruxtecan HER2-low mBC · Breast Cancer Res
Zanubrutinib vs ibrutinib CLL · NEJM · Phase III
Regorafenib mCRC third-line survival · Ann Oncol
Enfortumab vedotin + pembro urothelial · JCO
Belantamab mafodotin MM phase II update · Blood
Tucatinib + trastuzumab HER2+ mCRC · Lancet Oncol
Mirvetuximab IMGN853 platinum-resistant OC · ASCO
Cemiplimab cSCC final OS · JCO · Phase II
Atezolizumab + carboplatin in ES-SCLC · NEJM · Phase III
FOLFOX vs FOLFIRI first-line mCRC · JCO · Phase III
Tarlatamab OS benefit in relapsed SCLC · NEJM■■■
Sacituzumab govitecan in HR+ mBC · ASCO 2ify26
Lenvatinib + everolimus RCC subgroup · Lancet Oncol
Olaparib maintenance BRCA2+ pancreatic · NEJM
Nivolumab + AVD in untreated cHL · FDA■■■
Cabozantinib + atezolizumab HCC phase II · JCO
Pembrolizumab neoadjuvant TNBC 3-yr OS · ASCO
Tepotinib MET exon 14 NSCLC real-world · Lung Cancer
Iniparib in TNBC: final survival data · Cancer
Aca + venetoclax all-oral CLL · FDA AMPLIFY■■■
Selinexor + bortezomib in MM · Blood · Phase III
Ipilimumab + nivolumab MPM 5-yr OS · Lancet
Lorlatinib vs crizotinib ALK+ NSCLC update · NEJM
Durvalumab stage III NSCLC PACIFIC 5-yr · JTO
Trastuzumab deruxtecan HER2-low mBC · Breast Cancer Res
Zanubrutinib vs ibrutinib CLL · NEJM · Phase III
Regorafenib mCRC third-line survival · Ann Oncol
Enfortumab vedotin + pembro urothelial · JCO
Belantamab mafodotin MM phase II update · Blood
Tucatinib + trastuzumab HER2+ mCRC · Lancet Oncol
Mirvetuximab IMGN853 platinum-resistant OC · ASCO
Cemiplimab cSCC final OS · JCO · Phase II
CS
AI triage
■■■ Practice-Impacting
Tarlatamab · Nivolumab+AVD · Aca+Ven
3 studies · immediate action required
■■ Incremental
TALAPRO-2 · Relacorilant
2 updates · noteworthy evidence
Horizon
PATINA · Belzutifan · +3 more
5 signals · watch & monitor

Structured monitoring. Reduced clinical noise.

CS
CarcinoS

Editorial Framework

CarcinoS applies a structured classification model to evaluate clinical relevance across major oncology resources

Step 01
Continuous Surveillance
Automated monitoring across every major oncology source, updated continuously.
  • NEJM, Lancet, JCO, JAMA Oncology
  • ASCO, ESMO, ASH proceedings
  • FDA & EMA regulatory releases
  • Preprint & early-access publications
Step 02
Impact Scoring
Each study is evaluated against a structured clinical relevance framework.
  • Overall survival benefit
  • FDA / regulatory approval
  • Phase III trial evidence
  • Biomarker-defined populations
  • Quality of life & safety data
Step 03
Tier Assignment
Studies are classified into one of three clearly defined tiers.
■■■
Practice-Impacting
Immediate clinical relevance
■■
Incremental
Important but not practice-changing
Horizon
Early signals worth monitoring
CS
CarcinoS
🔔

Alert Discipline

Notifications are reserved exclusively
for practice-impacting evidence

CS
CarcinoS now
Practice-Impacting Update:
New evidence alters clinical practice
4:01
▋▋📶
CS
CarcinoS
Week of Apr 6
🔔 New alert · Practice-impacting
PRACTICE IMPACTING ■■■
Osimertinib adjuvant in stage IB–IIIA EGFR+ NSCLC
NEJM · ADAURA · FDA Approved
5-yr OS 88% vs 78%
Pembrolizumab added to FOLFOX in MSS mCRC
Lancet · KEYNOTE-651 · GI
OS HR 0.77 · 21.4 vs 15.9 mo
INCREMENTAL ■■ 1 update ›
Olaparib + cetuximab in BRCA-mutated HNSCC
JCO · Phase II · Head & Neck
ORR 41% vs 18%
HORIZON 3 signals ›
CAR-T in relapsed AML: phase I results
Blood · Phase I · Hematology
Home
🔔Updates
•••More

Common questions

Everything you need to know before signing up.

How often will I receive updates? +

CarcinoS delivers curated weekly updates inside the app covering the prior week's oncology literature. Push notifications are reserved for practice-impacting findings and will only be sent either as an alert to your phone or email based upon your preferences, when qualifying evidence emerges.

What disease sites are included? +

CarcinoS covers all major solid tumor oncology specialties including lung, breast, gastrointestinal, genitourinary, CNS, head & neck, gynecologic, melanoma, sarcoma, and hepatobiliary cancers. Coverage expands continuously.

Is any patient data involved? +

No. CarcinoS monitors the published oncology literature only. No patient records, clinical notes, or identifiable health information of any kind are ever collected or processed.

Who reviews and classifies the content? +

AI-assisted triage identifies and scores candidate papers against a structured clinical relevance framework. All tier assignments are reviewed with human editorial oversight from practicing oncologists before publication in the digest.

Which oncology specialties are covered? +

CarcinoS covers all major solid tumor oncology specialties including lung, breast, gastrointestinal, genitourinary, CNS, head & neck, gynecologic, melanoma, sarcoma, and hepatobiliary cancers. Coverage expands continuously.